AnitaKohliMD

Infectious Disease • Chandler, AZ

Physician

Join to view full profile

Dr. Kohli is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kohli's full profile

Already have an account?

Office
2201 W Fairview St
Ste 9
Chandler, AZ 85224
Phone+1 480-470-4000

Fax+1 480-686-8875

Education & Training

National Institutes of Health Clinical CenterFellowship, Infectious Disease, 2009 - 2011
University of Virginia Medical CenterResidency, Internal Medicine, 2006 - 2009
University of Virginia School of MedicineClass of 2006

Certifications & Licensure

AZ State Medical License 2015 - 2026
OH State Medical License 2023 - 2025
MD State Medical License 2009 - 2016
DC State Medical License 2012 - 2014
VA State Medical License 2006 - 2010
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Leukapheresis for Research on HCV-Coinfected Patients Start of enrollment: 2004 Jan 14
Completed
Combination Therapy for Chronic Hepatitis C Infection Start of enrollment: 2013 Jan 01
Completed
Phase 2
Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV Start of enrollment: 2014 Feb 01
Completed
Phase 2
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Start of enrollment: 2017 Aug 30
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

42 citations
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Stephen A Harrison, Manal F Abdelmalek, Guy Neff, Nadege Gunn, Cynthia D Guy
The Lancet. Gastroenterology & Hepatology. 2022-07-01
90 citations
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase I...
Naim Alkhouri, Robert Herring, Heidi Kabler, Zeid Kayali, Tarek Hassanein
Journal of Hepatology. 2022-09-01
19 citations
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
Eric J Lawitz, Bal Raj Bhandari, Peter J Ruane, Anita Kohli, Eliza Harting
Clinical Gastroenterology and Hepatology. 2023-01-01

Press Mentions

Arizona on the Cutting Edge of Innovative Research ProgramsMarch 4th, 2022
Merck’s Household Contacts Study Testing Molnupiravir Goes to a Connected Investigator in ArizonaSeptember 16th, 2021
Regeneron Clinical Trials of COVID Antibody Drugs Featured in NY TimesAugust 18th, 2020
Join now to see all